Expert Discusses Challenges, Risks of Ibrutinib as Chronic Lymphocytic Leukemia Treatment

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.

In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.

She addressed some of the challenges and risk of ibrutinib treatment for CLL.

Related Videos
Senior Male Research Scientist is Using a Tablet Computer in a Modern High-Tech Laboratory. Genetics and Pharmaceutical Studies and Researches | Image Credit: Gorodenkoff - stock.adobe.com
Acute psoriasis on the elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis | Image Credit: SNAB - stock.adobe.com
Portrait of a smiling female pharmacist, male colleague working with drugs in the background. | Image Credit: bnenin - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.